June 22, 2018 Article published in the Pharma’s Almanac, June 7, 2018
The evolution of CDMOs has moved rapidly and today is dominated by the production of complex monoclonal antibodies and recombinant proteins. Still, the market is dynamic and growing in value and volume, while broadening into new disease mechanisms and therapeutic modalities. At the same time, project management in drug development and manufacturing has become more challenging in line with ever-increasing regulatory requirements. In turn, this is driving more biotech and pharma companies to rely on CDMOs that have the capabilities, expertise and experience to rapidly move projects through the clinical development and marketing stages.
Rentschler Biopharma is leading this evolution with its "Strategy 2025" initiative. CDMOs must be solution partners, supporting clients from concept to market, which is creating a need for new types of strategic partnerships, for instance, Rentschler Biopharma's alliance with Leukocare AG, offering advanced formulation development solutions at every step of a drug product's development and manufacturing process. In addition, to address the full range of opportunities and to provide reliable full-service solutions from gene to vial, Rentschler Biopharma has entered a strategic partnership with Rentschler Fill Solutions for state-of-the-art aseptic fill and finish capabilities.
"Rentschler Biopharma has always been a technology leader, and the implementation of our Strategy 2025 initiative will ensure that we continue to be a partner of choice for our customers."
Download the full interview here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication